Clinical Trial Update: Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ruxolitinib in combination with pracinostat for myelofibrosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Pracinostat (pracinostat)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloproliferative Diseases | Phase 2 | Status: COMPLETED | Results posted: 2019-06-05